Coronavirus Analysis
COVID-19 MedTech Digest, April 24, 2020
Excerpts from the latest coronavirus analysis in MedTech Strategist, Market Pathways, and the Community Blog.
Subscribe now to read the full analysisWelcome to MyStrategist, an online experience like no other in the medical device industry.
MedTech Strategist's complimentary Community Blog focuses on the people and the passion behind the global device space. Sign up for our e-Newsletter to receive new articles and video interviews directly to your inbox. Trial today to unlock our subscriber-only content.
e-Newsletter BrowseTrial MyStrategist.com and unlock 7-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
Perspective & Commentary
Deloitte: Embracing Virtual Health to Help Medtech Companies Thrive
Virtual health is here to stay. Its use has increased dramatically during the COVID-19 pandemic, placing it firmly on the path to widespread adoption. How could this growth impact the medtech industry in a post-pandemic world? By Bill Murray, Specialist Executive, Deloitte Consulting LLP.
Subscribe now to read the full analysisDiscover the opportunities and challenges that impact the global medtech regulatory and reimbursement community with MedTech Strategist Market Pathways.
Subscribe Free Premier Issue Learn More
Coronavirus Analysis
Deloitte: The Post-COVID-19 Shutdown Rebound: How Medtech Companies Can Help Support Deferred Care and Procedure Recovery
The COVID-19 pandemic is testing medical technology companies’ ability to flex operations and help healthcare providers manage demand surges arising from the resumption of deferred care and procedures. To help support the rebound—and prepare for COVID-19’s potential long-term impacts on product, supply chain, and ecosystem capabilities—organizations should rethink their short- and long-term commercial effectiveness strategies. By Doug Billings, Deloitte Consulting LLP.
Subscribe now to read the full analysisDiscover the people, technologies, and companies in the global medical device industry that will impact your corporate strategy with MedTech Strategist.
Subscribe Now Learn More
Coronavirus Analysis
Deloitte: The Post-COVID-19 Shutdown Rebound: How Medtech Companies Can Help Support Deferred Care and Procedure Recovery
The COVID-19 pandemic is testing medical technology companies’ ability to flex operations and help healthcare providers manage demand surges arising from the resumption of deferred care and procedures. To help support the rebound—and prepare for COVID-19’s potential long-term impacts on product, supply chain, and ecosystem capabilities—organizations should rethink their short- and long-term commercial effectiveness strategies. By Doug Billings, Deloitte Consulting LLP.
Subscribe now to read the full analysis